Progress in radiation technology has been significant during the last decades in regard to imaging, treatment planning, and various forms of advanced dose delivery, e.g. Intensity Modulated and Image Guided Radiotherapy [@b0005; @b0010; @b0015]. The impact of these developments on the daily process of planning and performance of external beam radiotherapy has been dramatic [@b0355; @b0025]. However, the clinical evidence for an improvement of outcome has been rather limited, due to various reasons [@b0015].

Similar developments have taken place in brachytherapy. In gynaecology this has been mainly related to cervix cancer with the integration of (repetitive) 3D imaging (MRI) into the treatment planning process which had to be changed completely with the introduction of an adaptive target concept and a dose volume assessment balancing constraints for CTV and OAR [@b0030; @b0035]. The imaging modality of choice has become MRI with also some place for CT and maybe in future also for US [@b0040; @b0045]. Best technical improvements so far have been mainly the adaptation of classical applicators to become CT and MRI compatible and more recently the combination of intracavitary brachytherapy with a guided and focussed interstitial approach (Vienna ring applicator, [@b0050; @b0055; @b0060], Utrecht ovoid applicator [@b0060]).

These changes in brachytherapy technology seem to have a major direct impact on clinical outcome [@b0065]. For cervix cancer, in the past major improvements in regard to loco-regional, distant control and survival has been achieved through simultaneous chemo-radiotherapy which became standard of care in 1999, when five randomized trials were published [@b0070; @b0075; @b0080; @b0085; @b0090]. However, according to a recent joint and balanced meta-analysis of these trial groups the absolute benefit is pronounced, but limited which is in particular true for advanced disease [@b0095]. The absolute benefit for overall survival, disease free survival and local control at five years has been estimated as 6%, 8%, and 9%, respectively, which is well in line with what has been shown for other cancer sites, e.g. head and neck [@b0100]. The absolute overall survival benefit is largest for limited disease (I/IIA) with 10% and decreases in more advanced stage with 7% for IIB and 3% for III/IVA. These findings imply a significant need for further improvement, which may become possible through introduction of more intensive (adjuvant) chemotherapy [@b0105], but also through improvements of radiotherapy, in particular for more advanced disease.

The significant improvements of brachytherapy and EBRT technology during the last decades have not resulted in obvious major overall improvements in clinical outcome for cervical cancer according to what has been published, e.g. in the annual treatment reports, in regard to overall survival [@b0110] and according to published mono-institutional series [@b0115; @b0120; @b0125]. Nevertheless, major differences have been reported between different brachytherapy traditions for certain clinical scenarios, e.g. stage III, [@b0115; @b0125; @b0130; @b0135; @b0140; @b0145].

Favourable outcome after IGABT combined with 3D conformal external beam radiotherapy ± chemotherapy has been recently reported within the frame of some limited mono-institutional series applying different treatment schedules [@b0065; @b0150; @b0155; @b0160; @b0165]. IGABT seems to play a major role in the improvement of clinical outcome, in particular of local control in advanced cervical cancer with no increase in treatment related morbidity based on this mono-institutional experience. The large Vienna clinical series on a consecutive number of 145 patients including the learning period published in 2007 has played a major role in elucidating the issue of improvement of dose volume adaptation, dose escalation and clinical outcome.

In order to further clarify the present and future clinical impact of IGABT in cervical cancer, an analysis was performed to evaluate the dosimetric parameters and overall clinical outcome in the Vienna protocol period with applying the HR CTV concept and dose volume constraints for OAR according to the later GEC ESTRO Recommendations in 156 consecutive patients with mature 3-year follow-up data and to define the major clinical benefits to be expected from this new treatment method.

Material and methods {#s0010}
====================

Patient and tumour characteristics {#s0015}
----------------------------------

A total of 218 consecutive patients with cervical cancer were referred for definitive radiotherapy to the Radiation Oncology Department at the Vienna General Hospital between January 2001 and August 2008. For the current analysis, the following eligibility criteria were applied: patients with stage IB1 to IVA disease, who underwent the complete definitive radiotherapy and were followed in our department and who did not have a previous history of malignancy. Sixty-two patients were ineligible for this analysis: 30 with stage IVB disease, 5 as treated with palliative intent, 7 as referred to our department only for BT, 7 due to prior or simultaneous second malignancy (5 breast, 1 colon, 1 ovarian cancer); 13 patients due to incomplete radiotherapy for the following reasons: 2 refused brachytherapy, 3 did not finish brachytherapy because of missing compliance, 1 had progressive metastatic disease during EBRT, 4 interrupted treatment due to worsening medical conditions, and 3 died during treatment (1 from sepsis and pneumonia (no chemotherapy), 2 from cardiovascular disease).

One hundred and 56 patients with locally advanced cervical cancer met the eligibility criteria and were thus available for analysis. All patients were treated with curative intent in the Department of Radiotherapy applying a prospective in-house protocol with High Risk CTV and dose volume constraints for organs at risk (according to the Gyn GEC ESTRO Recommendations), with definitive radiotherapy consisting of 3D conformal external beam radiotherapy (EBRT) ± concomitant chemotherapy and High-Dose-Rate (HDR)-Brachytherapy. Median age was 58 years.

Patients were clinically staged according to the International Federation of Gynaecology and Obstetrics (FIGO) criteria [@b0170]: 12 stage IB1 (8%), 9 stage IB2 (6%), 4 stage IIA (3%), 88 stage IIB (56%), 5 stage IIIA (3%), 32 stage IIIB (21%) and 6 stage IVA (4%). Abdominal CT and pelvic MRI scans were performed in all patients, in order to determine local, regional and abdominal tumour spread, beside chest CT to rule out distant metastases. Tumour size as defined by clinical and MRI examination (maximum width) was 2--5 cm in 53 patients (34%) and more than 5 cm in 103 patients (66%).

One hundred thirty-four patients had squamous cell cancer (86%), 14 had adenocarcinoma (9%), 5 had adenosquamous carcinoma (3%) and 3 had other entities (2%). Ninety-six patients had a pelvic laparoscopic lymph node assessment (62%) including the removal of involved nodes. If this invasive procedure could not be performed (60 patients, medical reasons: age, Karnofsky status), CT and MRI were used to assess lymph node disease (size \>1 cm, loss of oval shape). In total, involved lymph nodes were detected in 75 patients (48%). One hundred and fourteen patients (73%) had concomitant chemotherapy, with 40 mg/m^2^ weekly cisplatin (selection due to medical reasons).

Treatment characteristics {#s0020}
-------------------------

For the detailed description of the general treatment and the treatment planning characteristics we refer in particular to the preceding report as published before recording the patient population treated from 1998--2003 [@b0065], but also to other publications from the Vienna group describing these procedures in detail [@b0030; @b0035; @b0050; @b0055; @b0175; @b0180; @b0185; @b0190; @b0195; @b0200]. In the following, specific issues are highlighted which are of importance for the update of some treatment and treatment planning parameters. In limited disease the treatment schedule was changed during the protocol period to pelvic 3D EBRT and 4 × 7 Gy HDR intracavitary brachytherapy. In patients with common iliac lymph node involvement, para-aortic radiotherapy was performed with a 3D conformal box technique (*n* = 37, 24%). In 69 patients with unfavourable spread of residual disease at the time of brachytherapy, a combined interstitial/intracavitary approach was used (44%) with the Vienna ring applicator in the majority of cases, and some modification in far advanced disease.

In 3 out of 156 patients, the MRI dataset was not sufficient to report meaningful DVH parameter. Dose volume constraints were 75 Gy in D~2cc~ for rectum and sigmoid and 100 Gy for the bladder in the beginning which were then gradually reduced to 70 Gy for rectum and sigmoid, if feasible and 90 Gy for the bladder [@b0190; @b0195; @b0200]. Dose and target coverage were adapted (D90), considering the institutional dose volume constraints for OAR. If appropriate and feasible, the dose was escalated, especially in advanced disease to arrive at a D90 of at least 85 Gy. For limited and good response disease, the high dose in the HR CTV (\>95 Gy D90) was not significantly reduced, only in case of violating dose volume constraints for OAR. The median treatment time was 48 days.

Endpoints {#s0025}
---------

Patients were followed for disease related parameters and adverse side effects every 3 months in the first 2 years, in 6 month intervals for the next 3 years and then annually. MRI was done every 6 months in the first 5 years.

Complete remission (CR) was defined as no evidence of disease 3 months after end of treatment, evaluated by clinical examination and MRI.

Pelvic failure was split in failure in true pelvis (cervix, uterine corpus, vagina and parametria) and pelvis (additional pelvic nodes).

Continuous complete remission (CCR) was defined as no evidence of disease after complete remission. It is subdivided in CCR true pelvis (CCR~tp~) and CCR pelvis (CCR~p~).

Progression free survival (PFS) was defined as no progression of disease after tumour biopsy. PFS was subdivided in PFS true pelvis (PFS~tp~) defined as local control, PFS pelvis (PFS~p~), defined as local and regional control, and PFS for distant metastases (PFS~dm~), defined as distant control, overall PFS is the freedom of local, regional and distant failure.

Overall survival (OS) and cancer specific survival (CSS) were defined as the period from the date of biopsy until the date of death and death by cervical cancer, respectively.

Late side effects are defined as any side effect appearing earliest 91 days after the end of treatment and are prospectively scored using the Late Effects in Normal Tissues-Subjective, Objective, Management and Analytic score (LENT SOMA, G0: no side effects, G4: worst side effect, LENT SOMA tables 1995). Side effects are reported as absolute number of events for G1--G4 morbidity. In addition, actuarial rates are given for G3 and G4 morbidity.

Statistical analysis and groups {#s0030}
-------------------------------

Patients were analysed who underwent the complete definitive radiotherapy treatment (see eligibility criteria). All parameters were calculated for tumours 2--5 cm and tumours \>5 cm and for the different stages. For the calculation, the SPSS-program was used (SPSS 15 for windows), applying the Kaplan--Meier method and log rank test. Outcome parameters were calculated at 3 years. Median follow up was 42 months for all patients and 58 months for patients alive. Ten patients were lost to follow up.

Results {#s0035}
=======

Dose volume adaptation and dose escalation {#s0040}
------------------------------------------

The mean D90 ± 1SD for the whole patient cohort was 93 ± 13 Gy, it was 96 Gy ± 15 Gy for tumours 2--5 cm and 91 Gy ± 11 Gy for tumours \> 5 cm. In the period from 2001--2003 the mean D90 was 90 ± 15 Gy in total, with 94 ± 16 Gy for tumours 2--5 cm and 87 ± 14 Gy for tumours \>5 cm. The mean D90 increased to 94 ± 10 Gy in the period from 2004--2008. The tumours 2--5 cm had a mean D90 of 100 ± 10 Gy, and the large tumours \> 5 cm a mean D90 of 93 ± 9 Gy, respectively. For both tumour size groups there was a mean 6 Gy increase in dose. Mean D~2cc~ for bladder was 86 ± 17 Gy, 65 ± 9 Gy for rectum and 64 ± 9 Gy sigmoid.

Disease control {#s0045}
---------------

A detailed overview on the different outcome parameters and comparisons in regard to tumour size and stage of disease is given in [Tables 1--4](#t0005 t0010 t0015 t0025){ref-type="table"} and in [Fig. 1](#f0005){ref-type="fig"}a--d with calculated values at a follow-up time of 3 years.

Complete remission was achieved in 151/156 patients (97%). Five patients had locally progressive disease. Recurrence in true pelvis occurred in 8 patients, 3 simultaneously with distant metastases. In addition, 5 patients had recurrence in the pelvic lymph nodes. Thirty-four patients had distant metastases alone. The events are shown in [Tables 1 and 2](#t0005 t0010){ref-type="table"}.

Continuous complete remission for the true pelvis (CCR~tp~) was 97% at three years. For small tumours it was 98%, while for large tumours CCR~tp~ was 95%.

Overall actuarial local control (3y) was 95%; 98% for tumours 2--5 cm, and 92% for tumours \>5 cm ([Table 2](#t0010){ref-type="table"}), 100% for IB, 96% for IIB, and 86% for IIIB ([Fig. 1](#f0005){ref-type="fig"}b and d). Actuarial progression free survival for distant metastases (3y) was 82% for all tumours, 87% for tumours 2--5 cm, 78% for tumours \>5 cm. According to tumour stage it was 88% for IB, 85% for IIB, 69% for IIIB, 60% for IVA.

Ninety patients of the whole patient cohort were still alive at the time of study (58%), 49 patients died because of cancer and 17 due to other reasons. Actuarial cancer specific survival (3y) was 74% for all patients, 83% for tumours 2--5 cm, 70% for tumours \>5 cm, 83% for IB, 84% for IIB, 52% for IIIB (see [Tables 2 and 4](#t0010 t0025){ref-type="table"}, [Fig. 1](#f0005){ref-type="fig"}a and c). Actuarial overall survival (3y) was in total 68%, 72% for tumours 2--5 cm, 65% for tumours \>5 cm, 74% for IB, 79% for IIB, 45% for IIIB (see [Tables 2 and 4](#t0010 t0025){ref-type="table"}, [Fig. 1](#f0005){ref-type="fig"}a).

Late adverse side effects {#s0050}
-------------------------

In regard to late morbidity altogether 188 grade 1 + 2 and 11 grade 3 + 4 events, respectively, were observed in 140 patients. Sixteen patients did not develop any side effects. For details we refer to [Table 3](#t0015){ref-type="table"}.

Actuarial rate for G3 + G4 morbidity was 2%/3% for the bladder, 4%/4% for the rectum, 0%/0%, for the bowel and 1%/3% for the vagina at 3/5 years, respectively.

### Bladder {#s0055}

Twenty patients had grade 1 and 12 patients grade 2 side effects (mainly urinary urgency and frequency). Three patients developed grade 3 late side effects in the bladder (urinary frequency, urge).

### Rectum {#s0060}

Eight patients experienced grade 1 and 6 patients grade 2 morbidity (mainly urgency and bleeding). Two patients suffered from massive rectal bleeding and also needed blood transfusions (G3). Three patients underwent stoma surgery (G4): 1 patient had rectal wall ulceration, 3--4 cm in diameter, which resulted in a fistula to the vagina, a second patient developed a recto-vaginal fistula, and a third patient rectal perforation.

### Bowel (including sigmoid) {#s0065}

Two patients developed grade 1 side effects suffering from mild diarrhoea with frequency 2--3 times daily (G1) and one patient had moderate diarrhoea up to 8 times daily (G2). No patient developed grade 3 or 4 side effects.

### Vagina {#s0070}

Grade 1 side effects were seen in 84 patients and grade 2 in 44 patients (mainly adhesions, teleangiectasia, dyspareunia). Two patients developed irreversible obliteration of more than two-thirds of the entire vaginal length (G3). One patient developed complete obliteration of the vagina (G4).

Discussion {#s0075}
==========

The clinical impact of MRI assisted dose volume adapted brachytherapy combined with 3D conformal EBRT ± cisplatin in locally advanced cervix cancer, based on a large single-institution study (*n* = 145), was first reported in our previous publication divided into a learning period and a subsequent protocol period following the GEC ESTRO Recommendations prospectively [@b0065]. There has been some additional evidence with favourable outcome provided from mono-institutional experience from IGR, Paris and Tata Memorial, Mumbai with MRI guided definitive adaptive PDR/HDR brachytherapy applying the GEC ESTRO Recommendations, in limited patient numbers, with no local recurrences in 45 patients (82% stage IB2/II) and 3 in 24 patients, respectively [@b0205; @b0210]. The CT experience published so far (Addenbrooke, Pittsburgh, Seoul) has revealed high local control rates (96%; 75%; 97%) in limited patient numbers [@b0155; @b0165; @b0215], with clear and significant improvements compared to historical controls, for example 96% vs. 76% and 97% vs 81% [@b0155; @b0165]. The Ultrasound experience also provides challenging results [@b0160]. The first prospective multicentre trial (STIC, France) comparing 2D to 3D CT image guided PDR brachytherapy in definitive radiotherapy at 2 years revealed a significant improvement in local control (74% vs. 79%) and a significant reduction in treatment related morbidity (G3/G4 14% vs. 1%) [@b0220].

The present study is an update of the Vienna results (2001--2003) [@b0065] with mature 3-year data on the protocol period (2001--2008) in a considerable number of 156 consecutive patients treated up to the start of the large prospective multicentre EMBRACE study (<http://www.embracestudy.dk>). The results clearly confirm that excellent local control rates can be achieved through MRI guided adaptive brachytherapy following a protocol according to the concepts of the GEC ESTRO Recommendations, with an overall local control rate of 95% at 3 years including 103/156 (66%) patients with tumour size \>5 cm. For the large tumours alone, the 3-year rate was 92%, for the tumours 2--5 cm 98%. This is an outstanding treatment result, which has to our knowledge not been achieved so far, neither in cervix cancer nor at any other tumour sites for advanced solid tumours by definitive radio(-chemo-)therapy alone. Local failures in this IGABT experience compare in absolute numbers very favourably with Vienna historical series for tumours \>5 cm ([Table 4](#t0025){ref-type="table"}): 7/103 (2001--2008) versus 12/40 (1998--2000, [@b0065]) and 22/124 (1993--97, [@b0225]).[1](#fn1){ref-type="fn"} This evident improvement was (mainly) in large tumours \>5 cm, with actuarial data for pelvic control raising from 67%/64% [@b0065; @b0225] in 124/40 patients to 90% in 103 patients.[2](#fn2){ref-type="fn"} This translates into an absolute local control benefit of 23--26% (actuarial) and a relative reduction in local failure of about 65% compared to the historical Vienna series. The major contribution to this major improvement is attributed to the change to MRI guidance with dose volume adaptation and dose escalation to a mean dose of 93 Gy for High Risk CTV (defined according to treatment response) and even much larger doses inside this HR CTV, during 2001--2008 (D90). There may be also some contribution through the introduction of simultaneous cisplatin chemotherapy in 1999 [@b0230] as the beneficial effect of radiochemotherapy on local control has been well described, however less pronounced in more advanced disease [@b0095]. In the period 1993--1997, radiochemotherapy was not applied, whereas in the recent series it was applied in 73%. The excellent regional control may be partly also attributable to laparoscopic pelvic lymph node dissection with macroscopic removal which was first introduced in 1997 and performed in 62% of patients in the recent series.

Current protocols on dose escalation in EBRT using advanced (functional) imaging, treatment planning and delivery techniques try to go into a similar direction aiming at the improvement of local control through volume adaptation and dose escalation at tumour sites where local failure is still very considerable, e.g. in NSCLC [@b0235] (new FP 7 protocol Amsterdam/Maastricht) and in head and neck cancer [@b0240]. In prostate cancer excellent results seem to be clinically achievable and superior to ultra high dose IMRT when implementing image guided prostate brachytherapy into treatment protocols e.g. for intermediate risk prostate cancer [@b0245], underlining the beneficial effect of very focussed dose escalation.

It has to be outlined that the recent cervix cancer experience reported here as well as in some of the dose escalation techniques briefly mentioned try to define analogue new ways of dose prescription which consist of balancing dose volume constraints for OAR and for target volume aiming at achieving the highest target dose as individually possible respecting the OAR dose volume constraints.

Within the protocol period 2001--2008, there was also an improvement in local control at 3 years for large tumours: 2001--2003: 6 failures out of 38 ([Table 2](#t0010){ref-type="table"} [@b0065]) versus 2004--2008: 1 failure out of 65 ([Table 2](#t0010){ref-type="table"}). This improvement is likely a result of continuous improvement in dose volume adaptation and dose escalation from mean 87 Gy in the first part of the protocol period to 93 Gy in the second part, also increasing the number of combined intracavitary/interstitial applications.

In regard to stage of disease, the major benefit is in advanced disease. For stage IIB/IIIB there are only 3/4 events out of 88/32 patients with a 96%/86% actuarial rate at 3 years, respectively ([Fig. 1](#f0005){ref-type="fig"}d). This compares very favourably with literature data [@b0125; @b0140]. However, there are some late events after 3 years, 1 in IIB and 4 in IIIB, however, mainly from the early protocol period. This implies that the failure rate at 5 years for IIIB will considerably drop (overall 8/32) and that there is obvious need for further improvement of local control, in particular for this subset of IIIB patients. Opposed to concomitant chemotherapy with local control improvement of 7% for IIB and 3% for III/IVA [@b0095], the effect of image guided brachytherapy seems to be in fact most pronounced in very advanced disease (tumours \>5 cm) with an absolute local control benefit of 23--26% in the Vienna series.

The mean D90 of 90 Gy during 2001--2003 became mean D90 of 94 Gy during 2004--2008. It has to be kept in mind that the mean D90 for tumours 2--5 cm has been 96 Gy for all patients, 94 Gy for the first period, 100 Gy for the second period, whereas for tumours \>5 cm the mean D90 has been 91 Gy for the whole period and 87 Gy for the first period and 93 Gy for the second period. Although this dose increase with excellent local control supports strongly the assumption of a dose effect for local control and although dose volume effects could already be clearly shown for advanced disease in the Vienna series [@b0180; @b0185], the large variation of dose values underlines that there is so far only limited evidence for well defined absolute dose values to be applied for a given clinical scenario (e.g. IB, IIB, IIIB). It also has to be taken into account that the dose variation through the various mono-institutional series with similar clinical outcome has been large so far [@b0250; @b0255; @b0260; @b0265].

Overall the clinical update from the recent Vienna series on local control compares well with what has been reported so far from partly smaller series with partly more limited follow up [@b0155; @b0160; @b0165; @b0205; @b0210; @b0215; @b0220] and indicates the large clinical benefit to be expected in regard to local control from this new image guided adaptive approach, in particular for advanced disease.

The improved local control in tumours \>5 cm seems to be associated with some increase in cancer specific survival at 3 years from 57%/40% in 1993--97/98--2000 [@b0065; @b0225] to 70% in 2001--2008, respectively, whereas no change was detectable in tumours 2--5 cm. CSS (3y) is 77%/80% and 83% for stage IB, 78%/71% and 84% in stage IIB, 59%/28% and 52% in stage IIIB, in the historical and recent periods, respectively ([Table 4](#t0025){ref-type="table"}, [Fig. 1](#f0005){ref-type="fig"}c). These findings may be interpreted as a trend to improved CSS, in particular for not very far advanced disease (stage IIB), whereas this is not seen in very advanced disease (stage IIIB). Such findings have clearly to be further clarified, also with longer follow up, as more events after the 3-year period will follow. At present the impact of the local image guided adaptive approach on cancer specific survival is not straightforward and demands clearly prospective clinical studies.

It is worthwhile to notice that morbidity was not increased in the protocol period. The tendency is rather a decrease ([Tables 3 and 4](#t0015 t0025){ref-type="table"}, compared to [@b0065; @b0225]). Severe morbidity (G3/G4) was low despite a very high radiation dose in the HR CTV: for the bladder the actuarial rate was 2%/3%, for the rectum 4%/4%, for the bowel 0%/0%, for the vagina 1%/3% at 3/5 years, respectively. This is in accordance with the recent findings from the STIC trial [@b0220].

There are limitations for these findings from the Vienna series: the current clinical results were achieved within a single institutional experience and are compared to a historical control of this institution with all the well known critical implications for historical comparisons \[compare footnote 2\]. The prognostic variables and the staging procedures were not comprehensively evaluated (e.g. lymph nodes, histology), the prospective evaluation focussed on tumour size, tumour volume and dose volume relations. The results may therefore be biased by such uncontrolled patient, tumour and staging parameters. The growing experience in CT assisted and then MRI guided adaptive brachytherapy of the Vienna investigators over more than 15 years is also a factor not well controlled. Such limitations will be partly overcome in the foreseeable future. A prospective collaborative International observational study on the parameters and the effects of MRI guided brachytherapy in locally advanced cervical cancer (EMBRACE) was initiated [@b0270] and also a retrospective multi-institutional review following the same principles for reporting (RetroEMBRACE). These studies will altogether provide data on minimum 1200 patients treated with IGABT during the next years [@b0275; @b0280] in addition to the data soon becoming available from a large prospective French trial (STIC) [@b0220].

Despite the growing importance of IGABT during the last years and multiple research activities in the field [@b0160; @b0165; @b0195; @b0200; @b0260; @b0265; @b0285; @b0290; @b0295; @b0300; @b0305; @b0310; @b0315; @b0320; @b0325; @b0330; @b0335; @b0340], there are still major issues to be clarified in order to bring IGABT to the next more mature levels. The most important issues are on DVH parameters and their correlation to outcome, both for CTV and OAR. This is of particular interest for limited and more advanced disease with good and poor response. The issue of dose volume constraints has to be clarified for the CTV, both for favourable and unfavourable advanced disease, with likely dose de-escalation and escalation [@b0345]. Furthermore, there is the dissemination issue as IGABT is at present mainly linked to MRI with limited availability in the western world and even less all over the world. It has to be clarified, to what extent imaging technologies like CT and/or US will be efficient enough to become an alternative and/or a complementary tool within IGABT, next to MRI.

Despite the significantly improved local control, the assumed associated improvement in (cancer specific) survival needs to be clarified, also in the frame of chemoradiation [@b0095]. Image guided adaptive brachytherapy will reduce local failure significantly, which will further make distant metastases the predominant pattern of failure (overall 52 with 34 distant compared to 18 loco-regional in this series, [Table 1](#t0005){ref-type="table"}). This needs new strategies to overcome distant failure more efficiently which may be intensified simultaneous chemo-radiotherapy [@b0105] and/or adjuvant chemotherapy [@b0350] and/or any form of "targeted therapies", in particular for patients identified -- based on poor prognostic factors -- to be at high risk of distant metastases. For future combined modality trials in cervix cancer (cytotoxic chemotherapy, targeted therapies), image guided adaptive brachytherapy should become a mandatory integral part in order to take advantage of the large clinical impact of this new treatment method in regard to local control and likely also survival.
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\[Both published Vienna series (1998--2000: MRI learning period [@b0065]; 1993--1997: radiotherapy alone/CT assisted BT treatment planning [@b0225] are taken for comparison, as both together are considered to represent best the full picture of the treatment in the preceding decade. The results from the period 1998--2000 were particularly poor\].

\[Actuarial pelvic control is given because the publication in 2000 only provides actuarial pelvic control data, with the majority of events being local, 22/26 ([Table 1](#t0005){ref-type="table"}[@b0225]). For the current series this is 7/8 pelvic failures being local, ([Tables 1 and 2](#t0005 t0010){ref-type="table"})\].

![Outcome after radiotherapy ± chemotherapy and image-guided adaptive brachytherapy. (a) Local control, cancer specific survival and overall survival for all 156 patients. (b) Local control and tumour size. (c) Cancer specific survival for FIGO stages IB, IIB, IIIB. (d) Local control for FIGO stages IB, IIB, IIIB.](gr1){#f0005}

###### 

Treatment response and site of relapse according to FIGO stage in 156 patients for the period of interest (3 years); numbers for the whole observation period are given in parentheses ().

  Stage   Total no.   Incomplete response   True pelvic recurrence   Pelvic lymph node recurrence   Distant relapse alone   Overall failure   No evidence of disease   
  ------- ----------- --------------------- ------------------------ ------------------------------ ----------------------- ----------------- ------------------------ -----------
  IA      1           0                     0 (0)                    0 (0)                          0 (0)                   0 (0)             0 (0)                    1 (1)
  IB      21          0                     0 (0)                    0 (0)                          1 (1)                   2 (3)             3 (4)                    18 (17)
  IIA     3           0                     0 (0)                    0 (0)                          0 (0)                   1 (1)             1 (1)                    2 (2)
  IIB     88          2                     0 (0)                    1 (2)                          1 (2)                   12 (15)           16 (21)                  72 (67)
  IIIA    5           0                     0 (0)                    0 (0)                          0 (0)                   2 (2)             2 (2)                    3 (3)
  IIIB    32          2                     0 (2)                    2 (3)                          2 (2)                   8 (11)            14 (20)                  18 (12)
  IVA     6           1                     0 (0)                    0 (1)                          0 (0)                   2 (2)             3 (4)                    3 (2)
  Total   156         5                     0 (2)                    3 (6)                          4 (5)                   27 (34)           39 (52)                  117 (104)
                                                                                                                                                                       

###### 

Outcome for 156 patients treated with radiotherapy ± chemotherapy and image guided adaptive brachytherapy. Events (*n*) at 3 years and after whole observation period, patients per subgroup (*n*), actuarial estimates (%).

                                        Protocol period image guided adaptive BT 2001--2008             
  ------------------------------------- ----------------------------------------------------- ---- ---- ----
  PFS~tp~ (local control)               156                                                   13   8    95
  2--5 cm                               53                                                    1    1    98
  \>5 cm                                103                                                   12   7    92
  PFS~p~ (pelvic control)               156                                                   18   12   91
  2--5 cm                               53                                                    3    3    95
  \>5 cm                                103                                                   15   9    90
  PFS~dm~ (distant failure free)        156                                                   34   27   82
  2--5 cm                               53                                                    9    6    87
  \>5 cm                                103                                                   25   21   78
  PFS~overall~ (overall failure free)   156                                                   52   39   75
  2--5 cm                               53                                                    12   8    83
  \>5 cm                                103                                                   40   31   70
  Cancer specific survival              156                                                   49   37   74
  2--5 cm                               53                                                    12   8    83
  \>5 cm                                103                                                   37   29   70
  Overall survival                      156                                                   66   49   68
  2--5 cm                               53                                                    22   16   72
  \>5 cm                                103                                                   44   33   65

PFS: progression free survival.

tp/p = True pelvis/pelvis (uterus, vagina, parametria/lymph nodes).

###### 

Late adverse effects (LENT SOMA) after radiotherapy ± chemotherapy and image guided adaptive brachytherapy in 156 patients (absolute numbers).

  Late adverse effects   Grade 0   Grade 1   Grade 2   Grade 3   Grade 4
  ---------------------- --------- --------- --------- --------- ---------
  Vagina                 23        84        44        2         1
  Bladder                121       20        12        3         0
  Rectum                 137       8         6         2         3
  Bowel/Sigmoid          152       2         2         0         0
  Total                            114       64        7         4
  without vagina                   30        20        5         3

###### 

Three year outcome in 418 patients after definitive radiotherapy ± chemotherapy in cervical cancer patients treated from 1993--1997 [@b0310], 1998--2000 [@b0155] and 2001--2008 at the Medical University of Vienna.

                                                              3 Year-OS (%)   3 Year-CSS (%)   3 Year-PFS pelvis (%)   3Year-G3/G4 morbidity (%)[⁎](#tblfn4){ref-type="table-fn"}                                                     
  ----------------------------------------------------- ----- --------------- ---------------- ----------------------- ------------------------------------------------------------ ---- ---- ---- ---- ----- ---- ---- ---- --- ---- ----
  Vienna: 1993--1997[a](#tblfn1){ref-type="table-fn"}   189   62              70               46                      40                                                           77   78   59   53   100   87   69   60   3   10   31
  Vienna: 1998--2000[b](#tblfn2){ref-type="table-fn"}   73    80              61               12                      25                                                           80   71   28   25   95    92   67   70   3   5    7
  Vienna: 2001--2008[c](#tblfn3){ref-type="table-fn"}   156   74              79               45                      33                                                           83   84   52   40   94    96   75   75   2   4    1

Radiotherapy alone; CT assisted brachytherapy treatment planning.

Radiotherapy ± chemotherapy; MRI guided adaptive brachytherapy: learning period.

Radiotherapy ± chemotherapy; MRI guided adaptive brachytherapy: protocol period.

Actuarial rates for G3/G4 morbidity (LENT-SOMA score).
